METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDING
The present disclosure relates to method of treating or preventing gastrointestinal (GI) bleeding in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
1 . A method of treating or preventing gastrointestinal (GI) bleeding in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).
2 . The method of claim 1 wherein the GI bleeding is caused by complications arising from left ventricular assist device (LVAD) implantation in the subject.
3 . The method of claim 2 wherein the GI bleeding is associated with inflammation arising from LVAD implantation in the subject.
4 . The method of claim 3 wherein the LVAD implantation is a bridge to transplant (BTT) or destination therapy (DT).
5 . The method of claim 4 wherein the subject is undergoing treatment or has been treated for heart failure.
6 . The method according to claim 6 wherein the heart failure is due to hypertension, cardiomyopathy (ischemic or non-ischemic), myocarditis, obesity, or diabetes.
7 . The method of claim 5 wherein the subject has advance ischemic or non-ischemic heart failure.
8 . The method according to any preceding claim , wherein the subject has an inflamed myocardium.
9 . The method according to any preceding claim , wherein the GI bleeding is associated with aortic stenosis.
10 . The method according to any preceding claim , wherein the GI bleeding is associated with von Willebrand's disease.
11 . The method according to any preceding claim , wherein the GI bleeding is associated with epistaxis.
12 . The method according to any preceding claim , wherein the GI bleeding is associated with a disorder selected from hemorrhoids, peptic ulcers, tears or inflammation in the esophagus, diverticulosis, diverticulitis, ulcerative colitis, Crohn's disease, colonic polyps, and cancer in the colon, stomach or esophagus.
13 . The method according to any preceding claim , wherein the cells and/or progeny thereof and/or soluble factors are administered to the subject by a catheter-based system.
14 . The method according to claim 9 wherein the cells, and/or progeny thereof and/or soluble factors are administered to the subject by transendocardial injection, intracoronary infusion, intravenous infusion, transepicardial injection. trans-atrial septal or coronary sinus approach.
15 . The method according to any preceding claim , wherein the mesenchymal lineage precursor or stem cells and/or progeny thereof and/or soluble factors derived therefrom are administered to the subject between about 1 and 7 days following diagnosis of heart failure.
16 . The method according to any preceding claim comprising administering a population of mesenchymal lineage precursor or stem cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.
17 . The method according to any preceding claim comprising administering a population of mesenchymal lineage precursor or stem cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.
18 . The method according to any preceding claim , wherein the population of mesenchymal lineage precursor or stem cells and/or progeny thereof are administered to the subject or the heart over multiple doses.
19 . The method according to any preceding claim comprising administering about 1.5×10 8 cells and/or progeny thereof.
20 . The method according to any preceding claim , wherein the population of mesenchymal lineage precursor or stem cells and/or progeny thereof are administered in the form of a composition together with a pharmaceutically acceptable carrier and/or excipient.